- Trial phase
- Approved
- Time to market
- Already approved and commercially available since 2015 (ARISTADA) and 2018 (ARISTADA INITIO).
- Why 4/10
- ARISTADA is already FDA-approved and commercially marketed with no pending PDUFA, pivotal readout, or regulatory decision for the drug itself. The next hard catalysts for Alkermes are orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027), not ARISTADA. Per the impact rubric, an approved drug with no pending binary catalyst scores 3-5.
ARISTADA is a mature commercial asset with no upcoming binary catalyst; the stock's next major value inflection points are the orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027). Watch ARISTADA's quarterly sales trajectory for competitive erosion signals from newer LAIs like UZEDY and Invega Hafyera, but the drug's patent protection through 2039 limits near-term generic risk.
Price Chart
Executive Summary
ARISTADA (aripiprazole lauroxil) is Alkermes' FDA-approved long-acting injectable antipsychotic for schizophrenia, first approved in 2015 with an initiation product (ARISTADA INITIO) approved in 2018. It offers flexible dosing every month, six weeks, or two months. The drug generated approximately $370M in 2025 net sales (about 31% of Alkermes' proprietary revenue) and is guided at $365M-$385M for full-year 2026. Patent protection extends to roughly 2039. ARISTADA is a mature commercial asset in a competitive LAI market against J&J's Invega franchise, Otsuka's Abilify Maintena, and newer entrants. The ALPINE Phase 3b study showed comparable efficacy to Invega Sustenna. With no pending regulatory catalysts for ARISTADA itself, the stock's next major catalysts are Alkermes' orexin pipeline readouts expected in 2027.
How It Works
ARISTADA is a long-acting injectable version of aripiprazole (Abilify), an atypical antipsychotic. It works by modulating dopamine and serotonin receptors in the brain to control schizophrenia symptoms. Instead of taking a daily pill, patients receive an intramuscular injection by a healthcare professional every month, every six weeks, or every two months, which releases the medication slowly over time. This helps patients stay on treatment and avoid relapses from missed daily doses.
Trial Status
ARISTADA is FDA-approved and commercially marketed. The Phase 3b ALPINE study (completed) compared ARISTADA head-to-head against Invega Sustenna and showed comparable efficacy. Alkermes continues to generate real-world evidence and present data at medical conferences.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalysts for ARISTADA specifically; it is a marketed product.
- Alkermes' broader catalysts include orexin portfolio readouts: Phase 3 alixorexton narcolepsy data expected mid-2027, and Phase 2 data for ALKS 7290 in ADHD.
- Quarterly ARISTADA net sales reports will continue to track competitive dynamics in the LAI antipsychotic market.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alkermes plc. 8-K ALKS ·Originating report